SD118: Amend Phase I

NDL submitted a protocol amendment to the U.K.'s MHRA to evaluate 2 higher dose levels of oral NSL-043 in an ongoing double-blind, placebo-controlled Phase I trial. A total of 40 healthy male voluntee...